Prescription medicine
Crizanlizumab Brand names: Adakveo
Crizanlizumab (Adakveo) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the crizanlizumab FDA label on DailyMed (effective June 4, 2026); every crizanlizumab label on DailyMed.
Highlights of the record
FDA label of June 4, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
Forms and strengths
- 10 mg/ml
Injection.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,389 through July 30, 2026
What is crizanlizumab used for?
From the label: indications and usageADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. ADAKVEO is a selectin blocker indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.
FDA pharmacologic class: Selectin Blocker.
Source: FDA drug label (ADAKVEO), Novartis Pharmaceuticals Corporation, effective June 4, 2026 (SPL set b2b7f8b4-fe9a-4a86-8129-9e43f99a20c6), via openFDA; the full label on DailyMed
What does the patient leaflet for crizanlizumab say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about ADAKVEO?ADAKVEO may cause serious side effects, including: Infusion-related reactions. Infusion-related reactions may happen during or within 24 hours of receiving an infusion of ADAKVEO. Infusion-related reactions may cause pain in different areas of your body. Your healthcare provider may slow down, temporarily stop, or completely stop your infusion with ADAKVEO if you have an infusion-related reaction. You may continue to receive ADAKVEO at a slower infusion rate and your healthcare provider may give you certain medicines before your infusion to lower your risk of getting an infusion-related reaction. Your healthcare provider should monitor you for signs and symptoms of infusion-related reactions and treat your symptoms as needed. Tell your healthcare provider right away if you get any of the following signs or symptoms of an infusion-related reaction: pain in different areas of your body headache fever chills or shivering nausea vomiting diarrhea tiredness dizziness sweating hives itching shortness of breath or wheezing ADAKVEO may interfere with a certain blood test. Tell your healthcare providers that you are receiving ADAKVEO before having any blood tests. ADAKVEO may interfere with a laboratory test to measure your platelet counts. See "What are possible side effects of ADAKVEO?" for more information about side effects.
Source: FDA drug label (ADAKVEO), Novartis Pharmaceuticals Corporation, effective June 4, 2026 (SPL set b2b7f8b4-fe9a-4a86-8129-9e43f99a20c6), via openFDA; the full label on DailyMed
Is there a generic for crizanlizumab (Adakveo)?
No generic crizanlizumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the crizanlizumab label say about other medicines?
The crizanlizumab label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Acetaminophen | warnings and precautions | Manage mild to moderate infusion-related reactions with temporary interruption of infusion, slowing the rate of infusion, symptomatic treatment (e.g., acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDS), opioids, antihistamines, intravenous fluids, and/or oxygen therapy). … |
Source: FDA drug label (ADAKVEO), Novartis Pharmaceuticals Corporation, effective June 4, 2026 (SPL set b2b7f8b4-fe9a-4a86-8129-9e43f99a20c6), via openFDA; the full label on DailyMed
What do FAERS reports show for crizanlizumab?
The FDA Adverse Event Reporting System holds 1,389 reports that list crizanlizumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 55 are coded as a death and 570 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Crizanlizumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other